This is huge news… heart disease is the number one killer globally.

“They found that Myc-driven activity in heart muscle cells is critically dependent on the level of another protein called Cyclin T1, made by a gene called Ccnt1, within the cells. When the Ccnt1 and Myc genes are expressed together, the heart switches into a regenerative state and its cells start to replicate. The results are published today in the journal Nature Communications.”

---

Researchers trying to turn off a gene that allows cancers to spread have made a surprising U-turn. By making the gene overactive and functional in the hearts of mice, they have triggered heart cell regeneration. Since adult hearts cannot usually repair themselves once damaged, harnessing the power of this gene represents major progress towards the first curative treatment for heart disease.

“This is really exciting because scientists have been trying to make heart cells proliferate for a long time. None of the current heart disease treatments are able to reverse degeneration of the heart tissue—they only slow progression of the disease. Now we’ve found a way to do it in a mouse model,” said Dr. Catherine Wilson, a researcher in the University of Cambridge’s Department of Pharmacology, who led the study.

The cell cycle—through which cells make copies of themselves—is tightly controlled in mammalian cells. Cancer develops when cells start to replicate themselves uncontrollably, and the Myc gene plays a key role in the process. Myc is known to be overactive in the vast majority of cancers, so targeting this gene is one of the highest priorities in cancer research. Much recent research has focused on trying to take control of Myc as a means of cancer therapy.

In the midst of the coronavirus epidemic/pandemic it bears remembering the application of hyperbaric oxygen therapy to the last major pandemic that impacted the United States in 1918, the Spanish Flu Pandemic. Death was primarily by pulmonary infection and its attendant hypoxemia and respiratory failure. The first application of hyperbaric medicine to a Spanish Flu victim was likely also the first application to a human being in the United States. In 1918 Dr. Orval Cunningham of Kansas City was brought a dying friend of a fellow physician. The patient was moribund and blue. Before Cunningham could perform his planned animal experiments he was asked to treat this dying patient. With just a one-hour treatment with compressed air at 1.68 atmospheres absolute the patient experienced improvement. Combined with additional hyperbaric treatments over the next 3 days this patient’s life was saved. Others followed.

Today’s coronavirus’ mortality is due to pulmonary infection and respiratory failure. While there are differences between the Spanish Flu and coronavirus the primary pathology is in the lungs, the first organ of contact with hyperbaric therapy beyond the skin. The ability of hyperbaric oxygen to penetrate inflammatory pulmonary secretions allows adequate oxygen to reach the blood while inhibiting the inflammatory process. Applied correctly, hyperbaric therapy may have utility in coronavirus patients similar to its life-saving history with the Spanish Flu. Harch Hyperbarics Inc 504 309‑4948 www.hbot.com

Some doctors are questioning the way ventilators are being used for people with serious cases of COVID-19. Why? More data shows a high death rate for patients treated under current ventilator practices.

At the same time, these doctors are saying their patients behave more like they have high altitude sickness than a viral infection. They talk about two different types of COVID-19 patients with differing severe lung problems.

While some patients respond to treatment as expected, doctors also describe patients whose lungs seem relatively fine, but who still can’t get enough oxygen into their blood. These patients may make up the majority with severe infections.

Despite a potential vaccine, the novel coronavirus could return on a seasonal basis, much like the flu, according to Seattle-based company Adaptive Biotechnologies.

That’s one of the reasons Adaptive is teaming up with pharmaceutical giant Amgen, which plans to use Adaptive’s proprietary technology platform to develop therapies to treat the virus.

Adaptive’s CEO Chad Robins says it’s the next big thing in the field of immune sequencing. They will screen blood samples of COVID-19 survivors, then identify which naturally occurring antibodies in the immune system can be used to neutralize the SARS-CoV-2 virus which causes the disease.